Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial

IMPORTANCE: In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, there was a significant reduction in the adjudicated primary outcome among patients with stable atherosclerotic vascular disease randomized to dual pathway inhibition (rivaroxaban 2.5 mg twice dai...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaba, Prakriti, Bhatt, Deepak L., Dagenais, Gilles R., Bosch, Jackie, Maggioni, Aldo P., Widimsky, Petr, Leong, Darryl, Fox, Keith A. A., Yusuf, Salim, Eikelboom, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679876/
https://www.ncbi.nlm.nih.gov/pubmed/36409491
http://dx.doi.org/10.1001/jamanetworkopen.2022.43201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679876/
https://www.ncbi.nlm.nih.gov/pubmed/36409491
http://dx.doi.org/10.1001/jamanetworkopen.2022.43201

Ejemplares similares